Recent efforts have shown in vitro and clinical efficacy of targeting IGF1R in MM using small molecule inhibitors or a humanized anti-IGF1R monoclonal antibody [34], [35], [36], [37]. The gene discussed is IGF1R; the disease is Miyoshi myopathy.